AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

05 Aug 2021 05:00:01 By Nasdaq GlobeNewswire

Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

15 Jul 2021 05:35:00 By Nasdaq GlobeNewswire

Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021

02 Jun 2021 15:30:00 By Nasdaq GlobeNewswire

Amarin to Present at Two Investor Conferences in June 2021

18 May 2021 05:05:00 By Nasdaq GlobeNewswire

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session

17 May 2021 15:05:02 By Nasdaq GlobeNewswire

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session

15 May 2021 07:00:00 By Nasdaq GlobeNewswire

Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session

04 May 2021 06:00:01 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update

29 Apr 2021 05:10:00 By Nasdaq GlobeNewswire

Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel

29 Apr 2021 05:00:00 By Nasdaq GlobeNewswire

Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2

22 Apr 2021 09:53:02 By Nasdaq GlobeNewswire